Incyte
INCYINCY · Stock Price
Historical price data
Overview
Incyte is a publicly traded, revenue-generating biopharmaceutical company with a market valuation of approximately $18.19 billion, built on a foundation of targeted small molecule science. Its commercial success is anchored by Jakafi® (ruxolitinib) in myelofibrosis and polycythemia vera, with a diversified pipeline extending into oncology and immunology. The company's strategy combines internal R&D excellence with strategic partnerships to expand its therapeutic footprint and commercial reach globally.
Technology Platform
Integrated small molecule discovery platform with deep expertise in kinase inhibition (particularly JAK) and immune modulation, utilizing computational chemistry, high-throughput screening, and translational medicine.
Pipeline
200| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Povorcitinib + Placebo | Hidradenitis Suppurativa (HS) | Phase 3 | |
| Ruxolitinib Cream + Vehicle Cream | Hidradenitis Suppurativa | Phase 3 | |
| Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + ... | Graft-versus-host Disease (GVHD) | Phase 3 | |
| Tafasitamab + Lenalidomide | Large B-Cell Lymphoma | Phase 3 | |
| Ruxolitinib cream + Vehicle | Non-segmental Vitiligo | Phase 3 |
Funding History
3FDA Approved Drugs
6
Company Timeline
IPO — $30.0M
Series A: $8.0M
Founded in Wilmington, United States
FDA Approval: OPZELURA
FDA Approval: ZYNYZ
FDA Approval: NIKTIMVO